脑脊液酶谱在阿尔茨海默病中的研究进展

摘要
图/表
参考文献(30)
相关文章 (15)

全文: PDF (553 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要阿尔茨海默病（AD）是一种与年龄相关的、渐进性的神经系统变性疾病，是导致老年期痴呆最常见的病因。AD进展缓慢，病情呈进行性加重，在AD的发生发展中，不同的阶段伴随着相应的病理生理改变，在AD痴呆阶段之前还存在一个从几年到几十年的痴呆前阶段，而AD患者脑脊液中的酶可作为反映疾病变化过程的生物标志物，对于AD的早期诊治具有重要的意义。本文将对脑脊液中的一些酶在AD中的研究现状进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张齐皓1
	2 刘辰庚1 王培昌1

关键词 ：阿尔茨海默病, 脑脊液, 酶, BACE1, KLK6, 基质金属蛋白酶

Abstract：Alzheimer′s disease (AD) is an age-related and progressive neurodegenerative disease, which is the most common disease leading to dementia. AD develops slowly and becomes severe progressively. In the development of AD, different stages are accompanied with corresponding pathophysiological changes, where the enzymes in the cerebrospinal fluid of patients with AD can be used as biomarkers to reflect the developing process of AD, and before the dementia stage of AD, there is a preclinical stage ranging from years to decades. In this way, it is of great significance to the early diagnosis and treatment of AD. This review focuses on the current research of some enzymes in the cerebrospinal fluid of AD.

Key words： Alzheimer′s disease Cerebrospinal fluid Enzyme BACE1 KLK6 Matrix metalloproteinases

基金资助:国家自然科学基金青年基金项目（81401734）；
首都医科大学本科生科研训练项目（XSKY2018148）；
北京市医院管理局青年人才培养“青苗”计划（QML20150804）；
国家重点研发计划项目（2016YFC1306301）。

通讯作者: 刘辰庚（1980.12-），男，副教授，副主任技师，硕士研究生导师，主要从事衰老和神经系统疾病机制研究和标志物筛选。

引用本文:

张齐皓1，2 刘辰庚1 王培昌1. 脑脊液酶谱在阿尔茨海默病中的研究进展[J]. 中国医药导报, 2019, 16(14): 19-22.
ZHANG Qihao1,2 LIU Chengeng1 WANG Peichang1. Advances of cerebrospinal fluid enzyme spectrum in Alzheimer′s disease. 中国医药导报, 2019, 16(14): 19-22.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I14/19

[1] Blennow K，de Leon MJ，Zetterberg H. Alzheimer′s disease [J]. Lancet，2006，368（9533）：387-403.
[2] Jack CJ，Knopman DS，Jagust WJ，et al. Tracking pathophysiological processes in Alzheimer′s disease：an updated hypothetical model of dynamic biomarkers [J]. Lancet Neurol，2013，12（2）：207-216.
[3] Dubois B，Feldman HH，Jacova C，et al. Advancing research diagnostic criteria for Alzheimer′s disease：the IWG-2 criteria [J]. Lancet Neurol，2014，13（6）：614-629.
[4] Hort J，Bartos A，Pirttila T，et al. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe [J]. Eur J Neurol，2010，17（1）：90-96.
[5] Schoonenboom NS，Reesink FE，Verwey NA，et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort [J]. Neurology，2012，78（1）：47-54.
[6] Thinakaran G，Koo EH. Amyloid precursor protein trafficking，processing，and function [J]. J Biol Chem，2008， 283（44）：29615-29619.
[7] Haass C，Kaether C，Thinakaran G，et al. Trafficking and proteolytic processing of APP [J]. Cold Spring Harb Perspect Med，2012，2（5）：a6270.
[8] Yan R，Bienkowski MJ，Shuck ME，et al. Membrane-anchored aspartyl protease with Alzheimer′s disease beta-secretase activity [J]. Nature，1999，402（6761）：533-537.
[9] Roberds SL，Anderson J，Basi G，et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain：implications for Alzheimer's disease therapeutics [J]. Hum Mol Genet，2001，10（12）：1317-1324.
[10] Luo Y，Bolon B，Kahn S，et al. Mice deficient in BACE1，the Alzheimer′s beta-secretase，have normal phenotype and abolished beta-amyloid generation [J]. Nat Neurosci，2001，4（3）：231-232.
[11] Singer O，Marr RA，Rockenstein E，et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model [J]. Nat Neurosci，2005，8（10）：1343-1349.
[12] Holsinger RM，McLean CA，Collins SJ，et al. Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer′s disease subjects [J]. Ann Neurol，2004，55（6）：898-899.
[13] Zhong Z，Ewers M，Teipel S，et al. Levels of beta-secretase（BACE1）in cerebrospinal fluid as a predictor of risk in mild cognitive impairment [J]. Arch Gen Psychiatry，2007，64（6）：718-726.
[14] Zetterberg H，Andreasson U，Hansson O，et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease [J]. Arch Neurol，2008，65（8）：1102-1107.
[15] Mulder SD，van der Flier WM，Verheijen JH，et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology [J]. J Alzheimers Dis，2010，20（1）：253-260.
[16] Petersen RC，Smith GE，Waring SC，et al. Mild cognitive impairment：clinical characterization and outcome [J]. Arch Neurol，1999，56（3）：303-308.
[17] Mattsson N，Zetterberg H，Hansson O，et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment [J]. JAMA，2009，302（4）：385-393.
[18] Hansson O，Zetterberg H，Buchhave P，et al. Association between CSF biomarkers and incipient Alzheimer′s disease in patients with mild cognitive impairment：a follow-up study [J]. Lancet Neurol，2006，5（3）：228-234.
[19] Shaw LM，Vanderstichele H，Knapik-Czajka M，et al.Cerebrospinal fluid biomarker signature in Alzheimer′s disease neuroimaging initiative subjects [J]. Ann Neurol，2009，65（4）：403-413.
[20] Rosen C，Andreasson U，Mattsson N，et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alz-heimer′s disease [J]. Neuromolecular Med，2012，14（1）：65-73.
[21] Perneczky R，Alexopoulos P. Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease [J]. Alzheimers Dement，2014，10（5 Suppl）：S425-S429.
[22] Savage MJ，Holder DJ，Wu G，et al. Soluble BACE-1 Activity and sAbetaPPbeta Concentrations in Alzheimer′s Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer′s Disease Neuroimaging Initiative-1 Baseline Cohort [J]. J Alzheimers Dis，2015，46（2）：431-440.
[23] Alexopoulos P，Thierjung N，Grimmer T，et al. Cerebrospinal Fluid BACE1 Activity and sAbetaPPbeta as Biomarker Candidates of Alzheimer′s Disease [J]. Dement Geriatr Cogn Disord，2018，45（3/4）：152-161.
[24] Alexopoulos P，Tsolakidou A，Roselli F，et al. Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid [J]. Alzheimers Dement，2012，8（4）：304-311.
[25] Mattsson N，Bremell D，Anckarsater R，et al. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism [J]. BMC Neurol，2010，10：51.
[26] Selnes P，Blennow K，Zetterberg H，et al. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid [J]. Cerebrospinal Fluid Res，2010，7：10.
[27] Menendez-Gonzalez M，Castro-Santos P，Suarez A，et al. Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer′s disease [J]. J Alzheimers Dis，2008，14（1）：59-67.
[28] Scarisbrick IA，Radulovic M，Burda JE，et al. Kallikrein 6 is a novel molecular trigger of reactive astrogliosis [J]. Biol Chem，2012，393（5）：355-367.
[29] Patra K，Soosaipillai A，Sando SB，et al. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer′s disease [J]. Alzheimers Res Ther，2018， 10（1）：9.
[30] Adair JC，Charlie J，Dencoff JE，et al. Measurement of gelatinase B（MMP-9）in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease [J]. Stroke，2004，35（6）：e159-e162.